TECregen

Biotech & Life Sciences · Basel, Switzerland · Founded 2023

Ligand-based therapies to restore thymus function and support lifelong immune health

Valuation $0–100M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

TECregen company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2023
Headquarters: Basel, Switzerland
Employees: 14
Open positions: None listed
Dealroom signal: 56.4

Website ↗LinkedIn ↗

client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorCardiology and cardiovascularsectorImmune SystemsectorSpinoutsectorBiotech and PharmasectorDT and LSsectorscience-based

Valuation & funding

TECregen funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Jan 2026	$13M	$50M	CARMA FUND Management · EOS Bioinnovation · Boehringer Ingelheim · HTGF	↗
SPINOUT✓Other financing	Jan 2023	$0	—	University of Basel	—

Showing 2 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

Year	Employees
2026	14
2025	7

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

TECregen website traffic

Latest recorded traffic for TECregen is 420 monthly website visits, down 30% over the last three months. TECregen's team grew 100% over the past year.

Latest monthly visits420 3-month web change-30% 1-year team growth+100%

Monthly website visits4 observations · Jul 2025–Feb 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

TECregen compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCimeio TherapeuticsDeveloping Shielded-Cell & Drug Pairs to increase cure rates for patients with hematologic malignancies, genetic and autoimmune diseases	Cambridge, United States	Operational	16	$50M	$200M
HEHemastatxAntibody therapies targeting VWF-related bleeding disorders, leveraging scientific research and clinical innovation	Allschwil, Switzerland	Operational
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational
STStratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases	Natick, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
EREna RespiratoryNasal spray boosting innate immunity against viruses	Melbourne, Australia	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
DEDesentumBiopharma company in Finland developing allergy vaccines that change the way the immune system reacts to allergens	Espoo, Finland	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

TECregen's talent

Book a demo to see the people

Team profiled 1 named & role-tagged

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on TECregen's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 6 investors entered at this stage

Boehringer Ingelheim

CARMA FUND Management

EOS Bioinnovation

HTGF

ZKB - Zürcher Kantonalbank

LifeSpan Vision Ventures

Other known 1 additional known investor

University of Basel

Global footprint

Where TECregen has talent and traffic

Workforce by country

4 countries with
team presence

🇨🇭 Switzerland66.7%

🇩🇪 Germany16.7%

🇫🇷 France8.3%

🇬🇧 United Kingdom8.3%

4 countries shown

In the news

Latest news about TECregen

Recent press, funding announcements, and product moves mentioning TECregen — open to read from the original sources.

See all news

Market sentiment

What the market is saying about TECregen

An AI-synthesized read of the highest-engagement posts about TECregen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TECregen’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.